Impact Biomedical price to book ratio IBO
Market value divided by the book value of the company's net assets, since 2024.
- Today, Nov 2, 2026
- 40.2×
- 2-year median
- 25.0×
- Against its 2-year history
- 61st
- percentile: 0 is its lowest day, 100 its highest
- 2-year range
- 2.8× to 84.1×
- Peer median
- 2.0×
Impact Biomedical's price to book ratio is 40.2× as of Nov 2, 2026.
That is above its 2-year median of 25.0×, close to the middle of its last 2 years.
Over that time it ranged from 2.8× in Mar 2025 to 84.1× in Mar 2026.
The median for 10 large drugmakers of a similar size is 2.0×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 40.2× | 26.8× | 84.1× |
| 2025 | 23.2× | 2.8× | 34.5× |
| 2024 | 6.7× | 5.4× | 15.7× |
Against its peers
Companies in Drug Manufacturers - General nearest Impact Biomedical's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| IBOImpact Biomedical | 40.2× |
| CRMDCorMedix | 0.9× |
| ARVNArvinas | 0.9× |
| PBYIPuma Biotechnology | 3.8× |
| IRWDIronwood Pharmaceuticals | n/m |
| ZVRAZevra Therapeutics | 2.8× |
| COLLCollegium Pharmaceutical | 2.5× |
| ABUSArbutus Biopharma | 3.1× |
| NATRNatures Sunshine Products | 1.2× |
| AMPHAmphastar Pharmaceuticals | 1.5× |
| OMEROmeros | n/m |
| Peer median | 2.0× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Impact Biomedical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.